Back to search results

Observational Study on rhBMP-2 Release for Bone Loss

This study is looking at how a bone-building protein, rhBMP-2 (recombinant human bone morphogenic protein-2), is released over time when combined with different carriers. Researchers are comparing E-PRF (enhanced Platelet-rich fibrin), a human blood product, to the FDA-approved absorbable collagen sponge (ACS), a combination of both, and E-PRF alone. The goal is to see if there are differences in how much rhBMP-2 is released from each carrier in a lab setting. This research could help improve treatments for bone loss. You might be able to join if you are an English-speaking patient of the UAB Dental School, at least 18 years old, and already planned for a periodontal procedure involving PRF. The study aims to measure the release of rhBMP-2 over six months.

Study design
This is an observational study with a planned enrollment of 20 participants. It is not specified if it is randomized or blinded.
What's involved
You would need to be a patient at the UAB Dental School and have a planned periodontal procedure that uses PRF, which involves a blood draw (venipuncture).
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint will be measured from baseline to 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04670965

Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An In Vitro Analysis

Not Yet Recruiting
Not specifiedAges 18–99Observational
University of Alabama at Birmingham
~20 participants
Updated 2026-04-20 on ClinicalTrials.gov
What's tested:E-PRF/rhBMP-2 (similar ratios)E-PRF/ACS/rhBMP-2rhBMP-2/E-PRFE-PRF only

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To quantify any difference between test groups in the release of rhBMP-2 after application to E-PRF and ACS, E-PRF, and ACS.
Measured over From baseline to 6 months

Conditions

Bone Loss

Explore related trials

Osteopenia

Where it's being run

1 sites across 1 states
Alabama1

Study leadership

  • Maria Geisinger, DDS, MS · PRINCIPAL_INVESTIGATOR · University of Alabama at Birmingham

Who to contact

Maria Geisinger, DDS,MS
[email protected]
934-4984
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

English speaking
At least 18 years old
Must be a patient of the UAB Dental School
Able to read and understand informed consent document
Previously treatment planned for a periodontal procedure that will utilize PRF, i.e. requiring venipuncture, as a part of the routine clinical care.

Exclusion

Non-English speaking
Less than 18 years old
Smokers/tobacco users (\>10 cigarettes/day)
Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing as assessed by Board Certified Periodontal faculty at UAB Department of Periodontology
Patient-reported serious adverse events reported with venipuncture, blood sample collection, and/or blood donation.

What this trial measures

  • To quantify any difference between test groups in the release of rhBMP-2 after application to E-PRF and ACS, E-PRF, and ACS.From baseline to 6 months

    The quanitites of rhBMP-2 at all time points from all groups will be compared using statistical analysis by two-way ANOVA with Bonferroni test.